(redirected from biomimetic)
Also found in: Dictionary, Medical, Encyclopedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
  • noun

Words related to bionics

application of biological principles to the study and design of engineering systems (especially electronic systems)

References in periodicals archive ?
DALLAS -- Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor, LLP are investigating the sale of BioMimetic Therapeutics, Inc.
Under the terms of the transaction, BioMimetic shareholders will receive only $1.
The CVR payments to BioMimetic shareholders are structured as follows:
CONTACT: Kearstin Patterson, Corporate Communications of BioMimetic Therapeutics, +1-615-236-4419, kpatterson@biomimetics.
Hirsch joins BioMimetic Pharmaceuticals from Smith & Nephew Orthopaedics, where he was President of their European business.
Chairman and Chief Executive Officer of BioMimetic Pharmaceuticals.
InterWest is excited to be supporting the BioMimetic team in their efforts to advance novel drug/device combinations for the treatment of degenerative diseases and debilitating injuries," stated Chris Ehrlich, Partner at InterWest Partners.
This biomimetic CO sensor is designed to mimic the human hemoglobin reaction to CO," says Dr.
Further, BioMimetic's actual results and the timing and outcome of events may differ materially from those expressed in or implied by the forward-looking statements because of risks associated with the marketing of BioMimetic's products, the approval process for and the commercialization of its product candidates, preclinical and clinical development activities, risks relating to potential securities claims, product liability claims, other litigation or claims or regulatory inquiries that have been and may be brought against BioMimetic and its officers and directors, regulatory oversight, and other risks detailed in BioMimetic's filings with the Securities and Exchange Commission.
Samuel Lynch, founder, president and CEO of BioMimetic Therapeutics.
Additionally, BioMimetic received regulatory approval in 2009 and 2011 to market the product in Canada and Australia, respectively and is awaiting an approvability decision in Europe, which is expected during the first half of 2012.
The Shuman Law Firm today announced that it is investigating potential claims against certain officers and directors of BioMimetic Therapeutics, Inc.